By continuing to use our site, you consent to the processing of cookies, user data (location information, type and version of the OS, the type and version of the browser, the type of device and the resolution of its screen, the source of where the user came from, from which site or for what advertisement, language OS and Browser, which pages are opened and to which buttons the user presses, ip-address) for the purpose of site functioning, retargeting and statistical surveys and reviews. If you do not want your data to be processed, please leave the site.

The Voice of People With Breast Cancer

What breast cancer drugs are available in Canada

MedSearch

Generic Name

Pertuzumab

Brand Name

Perjeta
HER2+
Stage Ib, II, III
Targeted Therapy
Hoffmann-La Roche Ltd
Injectable
Quebec
Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Northwest Territories, Nunavut, Ontario, Prince Edward Island, Saskatchewan, Yukon
No
Listed on Provincial Drug Formulary

PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the:

  • neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either >2 cm in diameter or node positive).
  • adjuvant treatment of patients with HER2-positive early breast cancer with lymph node positive and/or hormone receptor negative disease.

For information about pertuzumab (Perjeta) for late-stage breast cancer, click here.

Yes - Open

OnCare Roche Patient Support Program

Product Monograph

FAQ's